Core Insights - Perspective Therapeutics, Inc. has appointed Joel Sendek as the new Chief Financial Officer, effective immediately, bringing extensive experience in biotech finance and equity research [1][2][3] - Sendek has a proven track record, having raised over $2.5 billion in corporate finance transactions and recognized as an All-Star Analyst by The Wall Street Journal [2] - The company is advancing its clinical programs in the targeted alpha radiopharmaceutical field, with ongoing trials for neuroendocrine tumors, melanoma, and solid tumors [3][5] Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb for targeted radiation delivery [4] - The company is also working on complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [4] Clinical Programs - The company's clinical programs include VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, all currently in Phase 1/2a trials in the U.S. [5] - Perspective is expanding its regional network of drug product candidate finishing facilities to support clinical trials and commercial operations [5]